ABOUT THE JOURNAL

Top

Aims and scope of journal

Journal of Commercial Biotechnology is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with the current issues and industry trends.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners in the field, addressing topics such as:

  • Corporate strategy
  • Financing
  • Bioethics
  • Public and investor relations
  • Market analysis
  • Legal and regulatory issues.

The Journal is a unique forum for all those involved in biotechnology commercialisation, to present, share, and explore new ideas, latest thinking and best practice, making the Journal an indispensable guide for those developing projects and careers, within this fast moving field.

Every issue of Journal of Commercial Biotechnology publishes forward-thinking regular features from some of the leading names in biotechnology commercialisation.

By subscribing to Journal of Commercial Biotechnology, you will have access to the latest intelligence on cutting-edge life science research commercialisation, worldwide:

  • Peer-reviewed papers - original, high-quality articles from leading practitioners on the latest thinking, developments and techniques affecting biopharmaceutical, agrochemical and environmental companies
  • Legal & regulatory updates - providing expert guidance on the major legal and regulatory issues affecting the industry, compiled and prepared by Bird & Bird and Reed Smith
  • Financial account reports - summarizing the finances of the major established and newly-formed biotech companies
  • Book reviews - previewing forthcoming books in life science commercialisation

Journal of Commercial Biotechnology is essential reading for:

  • CEOs
  • Directors
  • Presidents
  • Vice Presidents
  • Heads of Business Development
  • Heads of Corporate Development
  • Commercial Directors
  • Chief Financial Officers
  • Investment Managers
  • Heads of Corporate Intellectual Property
  • Heads of Regulatory Affairs
  • Intellectual Property Lawyers and all those involved in the commercialisation of biotechnology.
Top

Abstracted/indexed in

Journal of Commercial Biotechnology is indexed and abstracted in:

  • ABI/INFORM
  • BioCommerce Abstracts
  • CAB Abstracts
  • CAB Health
  • Compendex
  • Elsevier Biobase
  • EMBASE
  • EMBiology
  • SCOPUS
Top

ISSN and eISSN

The international standard serial number (ISSN) for Journal of Commercial Biotechnology is 1462-8732 and the electronic international standard serial number (eISSN) is 1478-565X.

Top

Editorial Board

Journal of Commercial Biotechnology is guided by its Editors and eminent international Editorial Board of leading bioscience business professionals.

Managing Editor
Yali Friedman, Ph.D.
Washington, DC, USA
E-mail: JCBEditor@palgrave.com

Editorial Board

Arthur A. Boni, John R. Thorne Chair of Entrepreneurship; Associate Teaching Professor of Entrepreneurship; and Director, Donald H. Jones Center for Entrepreneurship, Tepper School of Business, Carnegie Mellon University, USA
V. Walter Bratic, Vice-President, Charles River Associates, USA
G. Steven Burrill, Chief Executive Officer, Burrill & Company, USA
Jeremy Curnock Cook, Executive Chairman, Bioscience Managers Limited, UK
Iraj Daizadeh, Managing Consultant, IBM, Global Business Services, Strategy & Change, Life Sciences Practice, USA
Mitch DeKoven, Director - Reimbursement and Market Access, Health Economics & Outcomes Research, IMS Consulting, USA
Spencer G. Feldman, Shareholder, Greenberg Traurig, USA
Sharon Finch, Director, Medius Associates, UK
Gerald S. "Sandy" Graham, Business and Management Consultant, Graham Consulting Group, USA
Emma Gutiérrez de Mesa, Scientific Officer, European Commission, Spain
David G Jensen, Managing Director, CareerTrax Inc., USA
Edward L. Korwek, Partner, Hogan & Hartson, USA
Thomas J. Kowalski, Partner, Frommer Lawrence & Haug LLP, USA
Weijun Li, Senior Research Scientist, Global Biological Development, Bayer HealthCare Pharmaceuticals, USA
Klaus Lindpaintner, Head, Roche Genetics & Roche Center for Medical Genomics, F.Hoffmann-La Roche AG, Switzerland
Arlen Meyers, Professor, Department of Otolaryngology, University of Colorado School of Medicine, USA
Henry Miller, Senior Research Fellow of Scientific Philosophy & Public Policy, Hoover Institution, Stanford University, USA
Stefan M. Miller, Hunton & Williams, LLP, USA
Robin Nott, Formerly, Cameron McKenna, UK
Andrea Rappagliosi, Vice President, Health Policy and Market Access, Merck Serono International, Switzerland
Michael Reiss, Professor of Science Education, Institute of Education, University of London, UK
Rebecca Robins, Global Marketing Director, Interbrand Wood Healthcare, UK
Anthony J. Russo, Chairman and CEO, Russo Partners, USA
Stephen M. Sammut, Senior Fellow, Wharton Health Care Systems and Entrepreneurial Programs and Venture Partner, Burrill & Company, USA
Simon Shohet, Head, Innovation and Technology Management, Sagentia Ltd, UK
Grant H. Skrepnek, Assistant Professor, The University of Arizona College of Pharmacy and Investigator, Center for Health Outcomes and PharmacoEconomic Research, USA
Anthony Stevens, Director, Medical Options, UK
Philip N. Sussman, Managing Partner, The Channel Group LLC, USA
Stan Yakatan, Chairman, Katan Associates, USA
Professor Michael Vitale, Director of Innovation Research Program, Melbourne Business School, Australia
Pieter Windels, Regulatory Scientist, Pioneer Overseas Corporation, Dupont Agriculture & Nutrition, Belgium

Legal & Regulatory Update Editors

Gerry Kamstra, Bird & Bird, UK
John Wilkinson, Reed Smith, UK

Editorial Office

  • Neil Henderson
    Publishing Manager
    Palgrave Macmillan
    Houndmills
    Basingstoke RG21 6XS, UK
    E-mail: n.henderson@palgrave.com
    Please clearly state for which journal you are contributing.